4-(polysubstituted pyrrolopyrimidine)-tetrahydroquinoxalone compounds, their preparation methods and uses
By synthesizing 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3-d]pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds, the limitations of existing cancer treatment methods have been overcome, achieving highly efficient inhibition of various cancer cells and enhanced safety, and showing potential for the development of novel anticancer drugs.
Patent Information
- Application Number
- CN202611443268.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-17
- Publication Date
- 2026-11-17
AI Technical Summary
Existing cancer treatments such as surgery, radiation therapy, and traditional drug therapy have limited effectiveness in combating tumor spread and latent lesions. Targeted drugs are prone to developing drug resistance, and there is a lack of anti-tumor drugs with novel mechanisms of action.
4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3-d]pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds were synthesized and exhibited broad-spectrum and selective antitumor activity by inhibiting tubulin aggregation and VEGFR2 activity.
These compounds exhibit significant inhibitory activity against proliferation in various cancer cells, demonstrate good safety and specificity, reduce toxic side effects, prevent drug resistance, and have the potential to be developed into novel anticancer drugs.
Smart Images

Figure CN123106685A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedicine, specifically, 4-(polysubstituted pyrrolopyrimidine)-tetrahydroquinoxalone compounds, their preparation methods, and uses; more specifically, it relates to 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3- d Pyrimidine-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds, their preparation methods and uses. Background Technology
[0003] Currently, clinical cancer treatment methods mainly include surgical intervention, radiotherapy, and drug therapy. In the early stages of cancer, surgical removal of the primary lesion is the main way to achieve a radical cure, but its effect on metastatic cancer cells or latent lesions is limited. Radiotherapy destroys cancer cell DNA through ionizing radiation, but it also damages normal cells near the cancerous tissue. Traditional drug therapy takes effect systemically to target metastases, but it has poor specificity, easily damages normal tissues, and can cause toxic side effects. Long-term use can also induce multidrug resistance. The development of targeted drugs has been one of the core focuses of anticancer drug development in the past 20 years. By inhibiting key proteins or signal transduction pathways in the pathogenesis of tumors, it aims to inhibit tumor growth and metastasis. It has advantages such as high specificity and low toxicity to normal cells. However, in clinical applications, it has been found that the body is prone to drug resistance due to factors such as target mutations. Therefore, the development of antitumor drugs with novel mechanisms of action remains a research hotspot in the field of antitumor drug development. Summary of the Invention
[0004] In view of this, the inventors conducted proliferation inhibition activity tests on the synthesized small molecule compounds in human lung cancer cells A549, human cervical cancer cells HeLa, and human astroblastoma cells U251, and discovered a series of 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3- d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one compounds exhibit significant inhibitory activity against tumor cell proliferation, demonstrating broad-spectrum and good selectivity (data shown in Table 1). Further mechanistic studies revealed that these compounds also possess microtubule aggregation inhibition (data shown in Table 2) and VEGFR2 inhibition (data shown in Table 3). In vivo evaluation in mice showed that the compounds have good safety at doses of 20 mg / kg and lower (see Table 3). Figure 1 ) and significant inhibitory effect on the proliferation of HeLa cells in nude mice cervical cancer xenografts (see Figure 2 Further research into these compounds may lead to the discovery of new antitumor or anticancer drugs with novel structural types.
[0005] To achieve the above objectives, the present invention adopts the following technical solution: In a first aspect, the present invention provides a class of compounds or pharmaceutically acceptable salts thereof having the structure shown in Formula I: Among them, R 1 The following are compounds: H, alkyl groups with 1 to 6 carbon atoms, cycloalkyl groups with 3 to 6 carbon atoms, alkylamino groups with 1 to 6 carbon atoms, cycloalkylamino groups with 3 to 6 carbon atoms, alkoxy groups with 1 to 6 carbon atoms, cycloalkoxy groups with 3 to 6 carbon atoms, halogens, vinyl groups, ethynyl groups, (hetero)aryl groups of 5 to 6 membered rings, arylamino groups of 5 to 6 membered rings, and aryloxy groups of 5 to 6 membered rings; R 2 H, alkyl groups with 1 to 6 carbon atoms, cycloalkyl groups with 3 to 6 carbon atoms, halogens, vinyl groups, ethynyl groups, acetyl groups, and (hetero)aryl groups with 5 to 6 membered rings; R 3 It is H, an alkyl group with 1 to 6 carbon atoms, or a cycloalkyl group with 3 to 6 carbon atoms; R 4 It can be H, alkyl groups with 1 to 3 carbon atoms, or halogens; X is CR 5 Or N; where R 5 It can be H, alkyl groups with 1 to 3 carbon atoms, or halogens; Y is CR 6 Or N; where R 6 The group can be H, alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 6 carbon atoms, alkoxy with 1 to 6 carbon atoms, cycloalkoxy with 3 to 6 carbon atoms, alkylamine with 1 to 6 carbon atoms, cycloalkylamine with 3 to 6 carbon atoms, halogen, cyano, methanesulfonyl, ester, carboxyl, amide, nitro, or amino.
[0006] Substituent definition As used in this article, the term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0007] The term "cyano" as used in this article refers to -CN.
[0008] The term "hydroxyl" as used in this article refers to -OH.
[0009] The term "amino" as used in this article refers to -NH2.
[0010] The term "vinyl" as used in this article refers to .
[0011] The term "acetylenol" as used in this article refers to .
[0012] The term "acetyl" as used in this article refers to .
[0013] As used herein, the term "alkyl" refers to a saturated straight-chain or branched monovalent hydrocarbon group having 1 to 6 carbon atoms, preferably 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Typical examples of "alkyl" include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, tert-pentyl, neopentyl, hexyl, etc.
[0014] As used in this article, the term "cycloalkyl" refers to a monocyclic saturated cyclic hydrocarbon group having 3 to 6 carbon atoms. Typical examples of "cycloalkyl" include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclopropyl, 2-methylcyclopentyl, etc.
[0015] The term "alkoxy" as used in this article refers to the -OR group. 7 , where R 7 Selected from alkyl and cycloalkyl groups as defined herein. Typical examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, etc.
[0016] The term "alkylamino" as used in this article refers to the group -NHR 8 , where R 8 Selected from alkyl and cycloalkyl groups as defined herein. Typical examples of "alkylamino" include, but are not limited to, methylamino, ethylamino, propylamino, butylamino, cyclopropylamino, etc.
[0017] The term "dialkylamino" as used in this article refers to the NR group. 8 R 9 , where R 8 R 9 Each is independently selected from alkyl and cycloalkyl groups as defined herein. Typical examples of "dialkylamino" include, but are not limited to, dimethylamino, diethylamino, dipropylamino, dibutylamino, dicyclopropylamino, etc.
[0018] The term "azacycloalkylamine" as used in this article refers to a group. Where n = 1~4, R 10 Selected from alkyl and halogen groups as defined herein. Typical examples of “azacycloalkylamine” include, but are not limited to, aziridine, 2-methylaziridine, aziridine, 2-methylaziridine, 3-methylaziridine, pyrrolidine, 2-methylpyrrolidine, 3-methylpyrrolidine, 2,5-dimethylpyrrolidine, 3,3-dimethylpyrrolidine, 3,3-difluoropyrrolidine, piperidine, 2-methylpiperidine, 3-methylpiperidine, 4-methylpiperidine, 2,3-dimethylpiperidine, 2,4-dimethylpiperidine, 2,5-dimethylpiperidine, 2,6-dimethylpiperidine, 4,4-difluoropiperidine, etc.
[0019] As used in this article, the term "(hybrid)aryl" refers to a saturated 5-membered ring containing only one O, N, or S atom, or a saturated 5-membered ring containing one O and one N atom, or one S and one N atom, or two N atoms, or a saturated 6-membered ring containing 0 to 2 N atoms.
[0020] As used herein, the term "(hetero)arylamine" refers to the (hetero)aryl group as described above, which is associated with a pyrrolo[2,3-] aryl group via an NH group. d Pyrimidine phase linkage; As used herein, the term "(hetero)aryloxy" refers to the (hetero)aryl group mentioned above, which is associated with a pyrrolo[2,3-] group via an O atom and a pyrrolo[2,3-] d Pyrimidine phase linkage.
[0021] In cases where the compound name used in this article differs from the chemical structural formula, the chemical structural formula shall prevail.
[0022] According to a preferred embodiment of the present invention, R in general formula I 1 It has structures such as methyl, Cl, alkylamine group with 1 to 6 carbon atoms, dialkylamine group with 1 to 6 carbon atoms, cycloalkylamine group with 3 to 6 carbon atoms, azircycloalkylamine group, alkoxy group with 1 to 6 carbon atoms, cycloalkoxy group with 3 to 6 carbon atoms, vinyl group, ethynyl group, etc. According to a preferred embodiment of the present invention, R in general formula I 2 It has structures such as H, halogen, methyl, ethyl, vinyl, ethynyl, acetyl, and (hetero)aryl groups of 5-6 membered rings; According to a preferred embodiment of the present invention, R in general formula I 3 It can be H or methyl; According to a preferred embodiment of the present invention, R in general formula I 4 It has structures such as H, alkyl groups with 1 to 3 carbon atoms, and halogens; According to a preferred embodiment of the present invention, X in general formula I is CR 5 Or N; where R 5 It has structures such as H, alkyl groups with 1 to 3 carbon atoms, and halogens; According to a preferred embodiment of the present invention, Y in general formula I is CR 6 Or N; where R 6 The group can be H, alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 6 carbon atoms, alkoxy with 1 to 6 carbon atoms, cycloalkoxy with 3 to 6 carbon atoms, alkylamine with 1 to 6 carbon atoms, cycloalkylamine with 3 to 6 carbon atoms, halogen, cyano, methanesulfonyl, ester, carboxyl, amide, nitro, or amino.
[0023] According to a preferred embodiment of the present invention, in general formula I, R1 Methyl, Cl; R 2 It can be H, halogen, methyl, ethyl, vinyl, ethynyl, acetyl, or a 5-membered ring (hetero)aryl, etc. R 3 It can be H or methyl; R 4 It has structures such as H, alkyl groups with 1 to 3 carbon atoms, and halogens; X is CR 5 Or N; where R 5 It has structures such as H, alkyl groups with 1 to 3 carbon atoms, and halogens; Y is CR 6 Or N; where R 6 The structure can be H, alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 6 carbon atoms, alkoxy with 1 to 6 carbon atoms, cycloalkoxy with 3 to 6 carbon atoms, alkylamine with 1 to 6 carbon atoms, cycloalkylamine with 3 to 6 carbon atoms, halogen, cyano, methanesulfonyl, ester, carboxyl, amide, nitro, or amino.
[0024] Preferably, the compound of general formula I of the present invention is selected from: The corresponding chemical name is: 4-(2-methyl-7-benzylpyrrolo[2,3-) d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I1) 4-[2-methyl-7-(4-fluorophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I2) 4-[2-methyl-7-(4-cyanophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I3) 4-[2-methyl-7-(4-methanesulfonylbenzyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I4) 4-{[2-methyl-4-(6-methoxy-3-oxo-1,2,3,4-tetrahydroquinoxalin-1-yl)pyrrolo[2,3- d Methyl pyrimidin-7-yl]methyl benzoate (compound I5) 4-{[2-methyl-4-(6-methoxy-3-oxo-1,2,3,4-tetrahydroquinoxalin-1-yl)pyrrolo[2,3- d Pyrimidin-7-yl]methylbenzoic acid (compound I6) 4-[2-methyl-7-(4-nitrophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I7) 4-[2-methyl-7-(4-aminophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I8) 4-[2-methyl-7-(4-methoxybenzyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I9) 4-[2-methyl-7-(3,4,5-trifluorophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I10) 4-[2-methyl-7-(4-pyridylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I11) 4-[2-methyl-7-(3-pyridylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I12) 4-{2-methyl-7-[(6-methylpyridin-3-yl)methyl]pyrrolo[2,3- d Pyrimidin-4-yl-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I13) 4-(2-methyl-5-iodo-7-benzylpyrrolo[2,3-) d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I14) 4-(2-methyl-5-acetyl-7-benzylpyrrolo[2,3-) d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I15) 4-[2-methyl-5-(furan-3-yl)-7-benzylpyrrolo[2,3-] dPyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I16) 4-(2-chloro-7-benzylpyrrolo[2,3-) d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I17) 4-(7-benzylpyrrolo[2,3-) d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I18) 4-(2,5-dichloro-7-benzylpyrrolo[2,3- d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I19) 4-[2,5-dichloro-7-(4-fluorobenzyl)pyrrolo[2,3- d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I20) 4-[2-chloro-6-methyl-7-(4-fluorophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I21) 4-[2-(furan-3-yl)-7-benzylpyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I22) 4-[2-(4-cyanoanilino)-7-benzylpyrrolo[2,3- d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I23) The compound of general formula I of this invention can be prepared by the following reaction route: Where R 1 R 2 R 3 R 4 The definitions of X and Y are as described in claim 1.
[0025] In the presence of acid or under neutral conditions, compounds of general formula II and 7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one hydrochloride (compound 1) are reacted in a solvent to give compounds of general formula I I1~I5, I7, I9~I15; further, I5 is hydrolyzed under alkaline conditions to give I6; I7 is reduced under palladium-carbon catalytic hydrogenation to give I8; I14 is coupled to I16 via a SUZUKI reaction catalyzed by a palladium reagent and a phosphine ligand. Alternatively, compound III can be reacted with compound 2 in a solvent in the presence of a base to give compound IV, which is then acylated with chloroacetyl chloride to give compound V. These compounds are then cyclized under basic conditions to give compounds I17, I19–I21 of general formula I. I17 is dechlorinated under palladium-carbon catalytic hydrogenation to give I18. I17 undergoes a SUZUKI coupling reaction catalyzed by a palladium reagent and a phosphine ligand to give I22, and a Buchward-Hartwig coupling reaction to give I23.
[0026] More specifically, Step (1) reaction: Under neutral conditions or in the presence of an acid (such as hydrochloric acid, sulfuric acid, hydrobromic acid or acetic acid) with a catalytic amount up to 2 equivalents, and if necessary with auxiliary reagents such as copper halide, bis(diphenylphosphine)ferrocene palladium dichloride / 1,1'-bis(diphenylphosphine)ferrocene, palladium acetate, X-Phos, etc., the compound of general formula II reacts with compound 1 in a solvent (such as DMF, acetonitrile, ethanol, tert-butanol, acetone, isopropanol, methanol, THF, toluene, 1,4-dioxane or DMSO, etc.) at a temperature below 200°C (e.g., temperature controlled by ice / water bath, oil bath or microwave) for 5 minutes to 24 hours to obtain compounds of general formula I I1~I5, I7, I9~I15; Step (2): I5 reacts with 1 to 10 equivalents of base (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, etc.) in a mixed solvent of organic solvent (e.g., methanol, ethanol, tetrahydrofuran, 1,4-dioxane, etc.) and water to give I6. I7 is reduced with hydrogen in an organic solvent (e.g., methanol, ethanol, tetrahydrofuran, ethyl acetate, etc.) in the presence of palladium on carbon (1% ~ 10% wt) to give compound I8; Step (3) reaction: I14 is reacted with furan-3-boronic acid or pinacol furan-3-boronic acid in solvents (such as DMF, acetonitrile, ethanol, tert-butanol, acetone, isopropanol, methanol, THF, toluene, 1,4-dioxane or DMSO and mixed solvents with water) in solvents (such as DMF, acetonitrile, ethanol, tert-butanol, acetone, isopropanol, methanol, THF, toluene, 1,4-dioxane or DMSO and mixed solvents with water) at temperatures below 200°C (e.g., temperature controlled by ice / water bath, oil bath or microwave) for 5 minutes to 24 hours to obtain compound I16.
[0027] Step (4) reaction: with 1 to 10 equivalents of base (e.g., cesium carbonate, sodium carbonate, sodium bicarbonate, triethylamine, pyridine, ... N , N -Dimethylaminopyridine, N , N Under the action of diisopropylethylamine, potassium carbonate, sodium tert-butoxide, cesium carbonate, potassium carbonate, etc., the compound of general formula III reacts with 4-methoxy-1,2-phenylenediamine (compound 2) in a solvent (such as DMF, acetonitrile, ethanol, tert-butanol, acetone, isopropanol, methanol, THF, toluene, 1,4-dioxane or DMSO, etc.) at a temperature below 200°C (e.g., temperature controlled by ice / water bath, oil bath or microwave) for 5 minutes to 24 hours to obtain the compound of general formula IV; Step (5) reaction: Compound of general formula V in 1 to 10 equivalents of base (e.g., sodium hydride, cesium carbonate, sodium carbonate, sodium bicarbonate, triethylamine, pyridine, ... N , N -Dimethylaminopyridine, N , N In the presence of diisopropylethylamine, potassium carbonate, sodium tert-butoxide, cesium carbonate, potassium carbonate, etc., chloroacetyl chloride reacts with chloroacetyl chloride in solvents (such as DMF, acetonitrile, ethanol, tert-butanol, acetone, isopropanol, methanol, THF, toluene, 1,4-dioxane, or DMSO, etc.) at temperatures below 200°C (e.g., temperature controlled by ice / water bath, oil bath, or microwave) for 5 minutes to 24 hours to yield compound V. Step (6) reaction: Compound of general formula V in 1 to 10 equivalents of base (e.g., sodium hydride, cesium carbonate, sodium carbonate, sodium bicarbonate, triethylamine, pyridine, ... N , N -Dimethylaminopyridine, N , NIn the presence of diisopropylethylamine, potassium carbonate, sodium tert-butoxide, cesium carbonate, potassium carbonate, etc., in solvents (such as DMF, acetonitrile, ethanol, tert-butanol, acetone, isopropanol, methanol, THF, toluene, 1,4-dioxane or DMSO, etc.), at temperatures below 200°C (e.g., temperature controlled by ice / water bath, oil bath or microwave), the reaction proceeds for 5 minutes to 24 hours to yield compounds of general formula I, I17, I19 to I21. Step (7): I17 is dechlorinated in an organic solvent (e.g., methanol, ethanol, tetrahydrofuran, ethyl acetate, etc.) in the presence of palladium on carbon (1% ~ 10% wt) and a base (e.g., triethylamine, diisopropylethylamine, etc.) with a catalytic amount up to 2 equivalents to give compound I18; I17 is then dechlorinated in the presence of a base (e.g., cesium carbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, etc.) with a catalytic amount up to 5 equivalents to give compound I18, and if necessary, with the auxiliary reagents cuprous halide, bis(diphenylphosphine)ferrocene palladium dichloride, 1,1'-bis(diphenylphosphine)ferrocene, palladium acetate, X-Phos Under the influence of the above conditions, furan-3-boronic acid or pinacol furan-3-boronic acid ester reacts with the following solvents (such as DMF, acetonitrile, ethanol, tert-butanol, acetone, isopropanol, methanol, THF, toluene, 1,4-dioxane or DMSO, and mixed solvents with water) at temperatures below 200°C (e.g., temperature controlled by ice / water bath, oil bath, or microwave) for 5 minutes to 24 hours to give compound I22; I17 reacts with a base (such as cesium carbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, etc.) in a catalytic amount up to 5 equivalents, and, if necessary, with auxiliary reagents such as cuprous halide, bis(diphenylphosphine)ferrocene palladium dichloride, 1,1'-bis(diphenylphosphine)ferrocene, palladium acetate, X-Phos Under the influence of the above conditions, 4-cyanoaniline is reacted with 4-cyanoaniline in a solvent (such as DMF, acetonitrile, THF, toluene, 1,4-dioxane or DMSO, etc.) at a temperature below 200°C (e.g., temperature controlled by ice / water bath, oil bath or microwave) for 5 minutes to 24 hours to obtain compound I23.
[0028] The compounds of this invention have shown strong inhibitory activity in various cancer cell assays. As described below, the compounds exhibited inhibitory activity comparable to or better than the positive control drugs paclitaxel and / or colchicine in assays of human non-small cell lung cancer A549 cells, human cervical cancer HeLa cells, and human glioma U251 cells. Therefore, the series of compounds of this invention possess broad-spectrum anticancer activity, and further research on them holds promise for the development of new drugs for treating various tumors or cancers.
[0029] The compounds of this invention can be used either on their own or as pharmaceutically acceptable salts or solvates. Pharmaceutically acceptable salts of compounds of general formula I include salts formed with pharmaceutically acceptable inorganic or organic acids, or with pharmaceutically acceptable inorganic or organic bases. Examples of suitable acid addition salts include salts formed with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, perchloric acid, fumaric acid, acetic acid, propionic acid, succinic acid, glycolic acid, formic acid, lactic acid, maleic acid, tartaric acid, citric acid, pyric acid, malonic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, hydroxynaphthoic acid, hydroiodic acid, malic acid, tannic acid, etc. N , N'- Salts formed from dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucosamine, and procaine. When referring to compounds of this invention, this includes compounds of general formula I and their pharmaceutically acceptable salts or solvates.
[0030] According to the present invention, the pharmaceutical composition comprises a compound of general formula I of the present invention and a conventional pharmaceutical carrier or excipient. The pharmaceutical composition can be administered, for example, orally or parenterally. The pharmaceutical compositions of the present invention can be prepared into various dosage forms according to conventional methods in the art, including but not limited to tablets, capsules, solutions, suspensions, granules, or injections, for administration, for example, orally or parenterally.
[0031] It should also be noted that the dosage and method of administration of the compounds of this invention depend on many factors, including the patient's age, weight, sex, natural health condition, nutritional status, the activity intensity of the compound, the time of administration, metabolic rate, the severity of the disease, and the subjective judgment of the treating physician. The preferred dosage is between 0.01 and 100 mg / kg body weight / day.
[0032] The beneficial effects of this invention are: (1) The 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3-) compound discovered in this invention possesses both microtubule aggregation inhibitory activity and VEGFR2 inhibitory activity. d Pyrimidine-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds have novel structures and are of great significance for enhancing drug specificity and efficacy, reducing toxic side effects, and preventing drug resistance.
[0033] (2) The 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3-) discovered in this invention dPyrimidine-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds exhibit strong inhibitory activity against the proliferation of human non-small cell lung cancer A549 cells, human cervical cancer HeLa cells, and human glioma U251 cells. They also show significant in vivo inhibitory effects on the proliferation of cervical cancer HeLa cell xenografts in nude mice, demonstrating promising potential for further development and application. Attached Figure Description
[0034] Figure 1 This is a schematic diagram showing the results of comparing the safety of different drug doses in mice in Example 27 of the present invention; Figure 2 This is an example of the in vivo antitumor activity of I2 against HeLa subcutaneous xenograft tumors in Example 28 of the present invention; wherein, A is a photograph of tumor-bearing mice in each group; B is a photograph of the tumor removed at the experimental endpoint; C is the tumor volume growth curve; D is the tumor weight statistics at the endpoint; E is the mouse body weight change curve during the dosing period; Vehicle is the solvent control group, PTX 10 mg / kg is the paclitaxel positive control group; TGI represents the tumor growth inhibition rate; * indicates the comparison with the solvent control group. P <0.05, **** indicates a difference compared to the solvent control group. P <0.0001. Detailed Implementation
[0035] The present invention will be explained below with reference to embodiments. Those skilled in the art will understand that the following embodiments are for illustrative purposes only and should not be considered as limiting the scope of the invention. Where specific techniques or conditions are not specified in the embodiments, they are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be obtained commercially.
[0036] Synthetic Method 1: Weigh out compound II (1 equivalent) and dissolve it in isopropanol. Add compound 1 (1.2-3 equivalents). Heat in an oil bath under N2 protection to 60-83°C for 6-24 hours. Monitor the reaction progress using TLC. After complete reaction, pour into ice water and adjust the pH to 7 with 5% NaHCO3 solution. Filter or extract. Separate the crude product by Flash column chromatography or recrystallize to obtain compounds I1-I5, I7, and I9-I15 of general formula I.
[0037] Synthetic Method 2: Weigh out compound III (1 equivalent) and dissolve it in isopropanol. Add 4-methoxy-o-phenylenediamine (compound 2, 1-3 equivalents) and diisopropylethylamine (1-6 equivalents). Heat in an oil bath under N2 protection until reflux for 4-24 h, or microwave at 80-150°C for 30 min-3 h. Monitor the reaction progress using TLC. After complete reaction, filter directly, wash with isopropanol, or pour the reaction solution into ice water, adjust the pH to 7-8 with 5% NaHCO3 solution, filter / extract, and separate the crude product by Flash column chromatography or recrystallize to obtain compound IV.
[0038] Synthetic Method 3: Dissolve compound IV (1 equivalent) in acetone or anhydrous DMF, add alkali (anhydrous K₂CO₃, anhydrous Cs₂CO₃, or NaHCO₃, 1-3 equivalents), add chloroacetyl chloride (1-2 equivalents) under ice bath cooling, and continue the reaction at this temperature for 30 min to 2 h. After complete reaction, pour into ice water and adjust the pH to 7 with 2N hydrochloric acid. Filter or extract, and separate or recrystallize the crude product using Flash column chromatography to obtain compound V.
[0039] Synthetic Method 4: Dissolve compound V (1 equivalent) in anhydrous DMF, add alkali (anhydrous K₂CO₃ or anhydrous Cs₂CO₃, 1-3 equivalents), react at room temperature for 4-12 hours, and after complete reaction, pour into ice water and adjust pH to 7 with 2N hydrochloric acid. Filter or extract, and separate the crude product by Flash column chromatography or recrystallize to obtain target compounds of general formula I17, I19-I21.
[0040] Synthesis and spectral data of some intermediates 2-[(2-chloro-7-benzylpyrrolo[2,3-]] d [Pyrimidin-4-yl)amino]-5-methoxyaniline (IV1) Synthetic Method Two. 2,4-Dichloro-7-benzylpyrrolo[2,3- d Pyrimidine (140 mg, 0.5 mmol), 2 (83 mg, 0.6 mmol), and diisopropylethylamine (174 μL, 1 mmol) were reacted by microwave heating to 120 °C for 30 min. The crude product was separated by Flash column chromatography (AcOEt: PE = 0 ~ 25%) to give 103 mg of the target compound as a white solid, yield: 54.2%. It was used directly in the next reaction.
[0041] 2-[(2,5-dichloro-7-benzylpyrrolo[2,3- d [Pyrimidin-4-yl)amino]-5-methoxyaniline (IV2) Synthetic Method Two. 2,4,5-Trichloro-7-benzylpyrrolo[2,3- d Pyrimidine (313 mg, 1 mmol), 2 (166 mg, 1.2 mmol), and diisopropylethylamine (348 μL, 2 mmol) were reacted by microwave heating to 120 °C for 1 h. After standing overnight, the mixture was filtered to give 336 mg of the target compound as a yellow-green solid, yield: 81.1%. This compound was used directly in the next reaction.
[0042] 2-({2,5-dichloro-7-[(4-fluorophenyl)methyl]pyrrolo[2,3- d Pyrimidine-4-ylamino)-5-methoxyaniline (IV3) Synthetic Method Two. 2,4,5-Trichloro-7-[(4-fluorophenyl)methyl]pyrrolo[2,3- d Pyrimidine (300 mg, 0.91 mmol), 2 (166 mg, 1.2 mmol), and diisopropylethylamine (348 μL, 2 mmol) were reacted by microwave heating to 120 °C for 1 h. After standing overnight, the mixture was filtered to give 302 mg of the target compound as a gray-black solid, yield: 76.8%. This compound was used directly in the next reaction.
[0043] 2-({(2-chloro-5-methyl-7-[(4-fluorophenyl)methyl]pyrrolo[2,3- d Pyrimidin-4-ylamino)-5-methoxyaniline (IV4) Synthetic general method two. 2,4-Dichloro-5-methyl-7-[(4-fluorophenyl)methyl]pyrrolo[2,3- d Pyrimidine (217 mg, 0.7 mmol), 2 (135 mg, 0.98 mmol), and diisopropylethylamine (244 μL, 1.4 mmol) were reacted by microwave heating to 120 °C for 1 h. The crude product was separated by Flash column chromatography (AcOEt:PE:DCM = 1:4:1) to give 135 mg of the target compound as a white solid, yield: 46.8%. It was used directly in the next reaction.
[0044] N -{2-[(2-chloro-7-benzylpyrrolo[2,3-] d [Pyrimidin-4-yl)amino]-5-methoxyphenyl}-2-chloroacetamide (V1) Synthetic Method 3. IV1 (80 mg, 0.21 mmol), chloroacetyl chloride (25 μL, 1 mmol), sodium bicarbonate (39 mg, 0.42 mmol). The crude product was separated by Flash column chromatography (AcOEt: PE = 0 ~ 30%) to give 67 mg of the target compound as a white solid, yield: 69.9%. It was used directly in the next reaction.
[0045] N -{2-[(2,5-dichloro-7-benzylpyrrolo[2,3- d [Pyrimidin-4-yl)amino]-5-methoxyphenyl}-2-chloroacetamide (V2) Synthetic method 3. IV2 (332 mg, 0.8 mmol), chloroacetyl chloride (77 μL, 0.96 mmol), sodium bicarbonate (134 mg, 1.6 mmol). 338 mg of the target compound was obtained as a gray solid, yield: 86.0%. It was used directly in the next reaction.
[0046] N -[2-({2,5-dichloro-7-[(4-fluorophenyl)methyl]pyrrolo[2,3- d [Pyrimidin-4-ylamino]-5-methoxyphenyl]-2-chloroacetamide (V3) Synthetic method 3. IV3 (260 mg, 0.6 mmol), chloroacetyl chloride (63 μL, 0.79 mmol), sodium bicarbonate (152 mg, 1.8 mmol). The crude product was separated by Flash column chromatography (AcOEt : DCM : PE = 1 : 10 : 10) to give 238 mg of the target compound as a white solid, yield: 78.0%. It was used directly in the next reaction.
[0047] N -[2-({2-chloro-5-methyl-7-[(4-fluorophenyl)methyl]pyrrolo[2,3- d [Pyrimidin-4-ylamino]-5-methoxyphenyl]-2-chloroacetamide (V4) Synthetic method 3. IV4 (103 mg, 0.25 mmol), chloroacetyl chloride (31 μL, 0.38 mmol), sodium bicarbonate (63 mg, 0.75 mmol). The crude product was separated by Flash column chromatography (AcOEt: PE = 0 ~ 40%) to give 112 mg of the target compound as a white solid, yield: 91.7%. It was used directly in the next reaction.
[0048] Example 1: 4-(2-methyl-7-benzylpyrrolo[2,3-) d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I1) Synthetic Method 1. 2-Methyl-4-chloro-7-benzylpyrrolo[2,3- d ]Pyrimidine (258 mg, 1 mmol), 2 (215 mg, 1 mmol), to give 196 mg of the target compound as a pale yellow solid, yield: 49.0%, 158-160 °C; 1 H NMR (500MHz, d -DMSO) δ 10.66 (s, 1H), 7.32 – 7.13 (m, 7H), 6.65 – 6.59 (m, 2H), 5.51(d, J = 3.5 Hz, 1H), 5.35 (s, 2H), 4.64 (s, 2H), 3.76 (s, 3H), 2.54 (s, 3H). 13 CNMR (125 MHz, d -DMSO) δ 168.50, 159.93, 157.57, 154.28, 152.66, 138.50, 133.71,129.03, 127.86, 127.71, 125.38, 124.32, 121.52, 107.68, 102.23, 102.14,101.00, 55.86, 49.43, 47.41, 26.23;HRMS(ESI): Calcd for C 23 H 22 N5O2 + [ M +H] + :400.176 8, found: 400.177 0.
[0049] Example 2: 4-[2-methyl-7-(4-fluorophenylmethyl)pyrrolo[2,3- d[Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I2) Synthetic Method 1. 2-Methyl-4-chloro-7-(4-fluorobenzyl)pyrrolo[2,3- d ]Pyrimidine (110 mg, 0.4 mmol), 2 (107 mg, 0.5 mmol), yielded 101 mg of the target compound, white solid, yield: 60.5%, melting point: 176-177 °C; 1 H NMR (400 MHz, d -DMSO) δ 10.66 (s, 1H), 7.28–7.24 (m, 2H), 7.18–7.11(m, 4H), 6.65–6.60 (m, 2H), 5.51 (d, J = 3.6 Hz, 1H), 5.33 (s, 2H), 4.64 (s, 2H), 3.76 (s, 3H), 2.55 (s, 3H). 13 C NMR (125 MHz, d -DMSO) δ 168.49, 162.90,160.97, 159.97, 157.59, 154.30, 152.58, 134.73, 134.70, 133.72, 129.93,129.87, 125.24, 124.34, 121.49, 115.90, 115.73, 107.69, 102.23, 102.17,101.07, 55.86, 49.42, 46.70, 26.23;HRMS(ESI): Calcd for C 23 H 21 FN5O2 + [ M +H] + :418.167 4, found: 418.167 6.
[0050] Example 3: 4-[2-methyl-7-(4-cyanophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I3) 2-Methyl-4-chloro-7-(4-cyanophenylmethyl)pyrrolo[2,3- dPyrimidine (113 mg, 0.4 mmol), 2 (108 mg, 0.5 mmol), yielded 96 mg of the target compound as a light gray solid, yield: 56.5%, melting point: 222-224 °C; 1 H NMR (500 MHz, d -DMSO)δ 10.67 (s, 1H), 7.77 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 4.0 Hz, 1H), 7.19 (d, J = 9.0 Hz, 1H), 6.65 (d, J = 3.0 Hz, 1H), 6.63 (dd, J = 8.5&3.0 Hz, 1H), 5.46 (s, 2H), 4.65 (s, 2H), 3.77 (s, 3H), 2.52(s, 3H).HRMS(ESI): Calcd for C 24 H 21 N6O2 + [ M +H] + : 425.172 1, found: 425.172 9.
[0051] Example 4: 4-[2-methyl-7-(4-methanesulfonylbenzyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I4) Synthetic Method 1. 2-Methyl-4-chloro-7-(4-methanesulfonylbenzyl)pyrrolo[2,3- d Pyrimidine (135 mg, 0.4 mmol), 2 (107 mg, 0.5 mmol), yielded 92 mg of the target compound as a pale gray solid, yield: 48.2%, melting point: 250 °C (carbonized). 1 H NMR (500 MHz, d -DMSO) δ 10.67 (s, 1H), 7.86 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 3.5 Hz, 1H), 7.19 (d,J = 8.7 Hz, 1H), 6.65(d, J = 3.0 Hz, 1H), 6.63 (dd, J = 8.7, 3.0 Hz, 1H), 5.55 (d, J = 3.5 Hz, 1H), 5.48(s, 2H), 4.65 (s, 2H), 3.77 (s, 3H), 3.17 (s, 3H), 2.53 (s, 3H). 13 C NMR (125MHz, d -DMSO) δ 168.48, 160.11, 157.64, 154.37, 152.72, 144.38, 140.32, 133.77,128.37, 127.83, 125.41, 124.37, 121.46, 107.72, 102.20, 101.36, 101.31,55.90, 49.43, 47.01, 43.96, 26.23.HRMS(ESI): Calcd for C 24 H 24 N5O4S + [ M +H] + :478.154 4, found: 478.155 2.
[0052] Example 5: 4-{[2-methyl-4-(6-methoxy-3-oxo-1,2,3,4-tetrahydroquinoxalin-1-yl)pyrrolo[2,3- d Methyl pyrimidin-7-yl]methyl benzoate (compound I5) Synthetic Method 1. 4-[(4-chloro-2-methylpyrrolo[2,3-] d Methyl pyrimidin-7-yl)methyl]benzoate (126 mg, 0.4 mmol), 2 (108 mg, 0.5 mmol), yielded 99 mg of the target compound as a pale yellow solid, yield: 54.1%, melting point: 239-241 °C; 1 H NMR (500 MHz, d -DMSO) δ 10.67 (s, 1H), 7.89 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 7.20 – 7.17 (m, 2H), 6.65 (d,J = 2.5 Hz, 1H), 6.62(dd, J = 8.5, 2.5 Hz, 1H), 5.54 (d, J = 3.5 Hz, 1H), 5.45 (s, 2H), 4.65 (s, 2H), 3.82 (s, 3H), 3.77 (s, 3H), 2.52 (s, 3H).HRMS(ESI): Calcd for C 25 H 24 N5O4 + [ M +H] + :458.182 3, found: 458.183 0.
[0053] Example 6: 4-{[2-methyl-4-(6-methoxy-3-oxo-1,2,3,4-tetrahydroquinoxalin-1-yl)pyrrolo[2,3- d Pyrimidin-7-yl]methylbenzoic acid (compound I6) At room temperature, I5 (68 mg, 0.15 mmol) was dissolved in a mixture of 3 mL tetrahydrofuran and 3 mL water, and lithium hydroxide (24 mg, 1 mmol) was added. The mixture was stirred overnight, and the reaction was monitored by TLC until complete. The reactants were poured into approximately 50 mL of ice water, and the pH was adjusted to 3 with 2N HCl to precipitate the solid. The solid was filtered, dried, and yielded 59 mg of the target compound as a light gray solid. Yield: 89.4%, melting point: 244-246 °C. 1 H NMR (500 MHz, d -DMSO) δ 12.91 (s, 1H), 10.67 (s, 1H), 7.88 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 7.22 – 7.14 (m, 2H), 6.72 – 6.58 (m,2H), 5.55 (d, J = 3.5 Hz, 1H), 5.44 (s, 2H), 4.66 (s, 2H), 3.77 (s, 3H), 2.54(s, 3H); 13 C NMR (125 MHz, d-DMSO) δ 168.47, 167.46, 160.00, 157.60, 154.29,152.70, 143.43, 133.73, 130.30, 130.09, 127.61, 125.44, 124.34, 121.46,107.68, 102.24, 102.15, 101.22, 55.85, 49.43, 47.18, 26.19;HRMS(ESI): Calcdfor C 24 H 22 N5O4 + [ M +H] + : 444.166 6, found: 444.167 8.
[0054] Example 7: 4-[2-methyl-7-(4-nitrophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I7) Synthetic Method 1. 2-Methyl-4-chloro-7-(4-nitrophenylmethyl)pyrrolo[2,3- d ]Pyrimidine (103 mg, 0.34 mmol), 2 (107 mg, 0.5 mmol), yielded 85 mg of the target compound as a yellow solid, yield: 56.3%, melting point: 248-249 °C; 1 H NMR (500 MHz, d -DMSO) δ 10.67 (s, 1H), 7.89 (d, J = 8.5 Hz, 2H), 7.27 (d, J =8.5 Hz, 2H), 7.20–7.17 (m, 2H), 6.65 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5Hz, 1H), 5.54 (d, J = 3.5 Hz, 1H), 5.45 (s, 2H), 4.65 (s, 2H), 3.82 (s, 3H), 3.77 (s, 3H), 2.52 (s, 3H).HRMS(ESI): Calcd for C 23 H 21 N6O4 + [ M +H]+ : 445.161 9, found: 445.162 6.
[0055] Example 8: 4-[2-methyl-7-(4-aminophenylmethyl)pyrrolo[2,3- d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I8) At room temperature, I7 (30 mg, 0.067 mmol) was dissolved in 5 mL of ethyl acetate, and Pd / C (15 mg, 5% wet wt) was added. The reaction was carried out under a hydrogen atmosphere for 4 h, and the reaction was monitored by TLC until complete. Pd / C was removed by diatomaceous earth filtration, and ethyl acetate was removed under reduced pressure. The crude product was subjected to Flash column chromatography (ethyl acetate: petroleum ether = 0 ~ 60%) to give 21 mg of the target compound as a yellowish-brown solid, yield: 75.1%, melting point: 136-137 °C. 1 H NMR (500 MHz, d -DMSO) δ 10.65 (s, 1H), 7.14 (d, J =8.5 Hz, 1H), 7.08 (d, J = 3.5 Hz, 1H), 6.94 (d, J = 8.5 Hz, 2H), 6.64 (d, J = 2.5Hz, 1H), 6.60 (dd, J = 8.5, 2.5 Hz, 1H), 6.47 (d, J = 8.5 Hz, 2H), 5.76 (s, 1H), 5.46 (d, J = 3.5 Hz, 1H), 5.12 (s, 2H), 5.04 (s, 2H), 4.63 (s, 2H), 3.76 (s, 3H), 2.56 (s, 3H). 13 C NMR (125 MHz, d -DMSO) δ 168.50, 159.69, 157.49, 154.15,152.45, 148.59, 133.64, 129.13, 125.15, 125.11, 124.22, 121.58, 114.21,114.19, 107.63, 102.15, 100.65, 55.82, 49.43, 47.26, 26.24.HRMS(ESI): Calcdfor C23 H 23 N6O2 + [ M +H] + : 415.187 7, found: 415.188 6.
[0056] Example 9: 4-[2-methyl-7-(4-methoxybenzyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I9) Synthetic Method 1. 2-Methyl-4-chloro-7-(4-methoxybenzyl)pyrrolo[2,3- d ]Pyrimidine (115 mg, 0.4 mmol), 2 (106 mg, 0.5 mmol), yielded 80 mg of the target compound as a pale yellow solid, yield: 46.6%, melting point: 193-195 °C; 1 H NMR (500 MHz, d -DMSO) δ 10.65 (s, 1H), 7.19 – 7.12 (m, 4H), 6.86(d, J = 8.7 Hz, 2H), 6.64 (d, J = 2.8 Hz, 1H), 6.60 (dd, J = 8.8, 2.8 Hz, 1H), 5.48(d, J = 3.6 Hz, 1H), 5.26 (s, 2H), 4.63 (s, 2H), 3.76 (s, 3H), 3.70 (s, 3H), 2.55 (s, 3H); HRMS(ESI): Calcd for C 24 H 24 N5O3 + [ M +H] + : 430.187 4, found: 430.1878.
[0057] Example 10: 4-[2-methyl-7-(3,4,5-trifluorophenylmethyl)pyrrolo[2,3- d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I10) Synthetic Method 1. 2-Methyl-4-chloro-7-(3,4,5-trifluorobenzyl)pyrrolo[2,3-d Pyrimidine (125 mg, 0.4 mmol), 2 (107 mg, 0.5 mmol), yielded 111 mg of the target compound as a pale yellow solid, yield: 61.9%, melting point: 200-202 °C; 1 H NMR (400 MHz, d -DMSO) δ 10.66 (s, 1H), 7.20 – 7.14 (m, 4H), 6.61 –6.64 (m, 2H), 5.54 (d, J = 3.6 Hz, 1H), 5.34 (s, 2H), 4.65 (s, 2H), 3.77 (s,3H), 2.54 (s, 3H). 13 C NMR (125 MHz, d -DMSO) δ 168.47, 160.14, 157.63, 154.34,152.60, 133.73, 125.14, 124.35, 121.43, 112.62, 112.58, 112.49, 112.45,107.70, 102.24, 101.41, 55.86, 49.40, 46.35, 26.20; HRMS(ESI): Calcd forC 23 H 19 F3N5O2 + [ M +H] + : 454.148 5, found: 454.149 0.
[0058] Example 11: 4-[2-methyl-7-(4-pyridylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I11) Synthetic Method 1. 2-Methyl-4-chloro-7-(4-pyridylmethyl)pyrrolo[2,3- d ]Pyrimidine (104 mg, 0.4 mmol), 2 (108 mg, 0.5 mmol), yielded 95 mg of the target compound as a light gray solid, yield: 59.3%, melting point: 195-197 °C; 1 H NMR (500 MHz, d -DMSO) δ 10.67 (s, 1H), 8.48 (d, J= 6.0 Hz, 2H), 7.22–7.19 (m, 2H), 7.06 (d, J = 6.0 Hz, 2H), 6.66–6.62 (m, 2H), 5.56 (d, J = 3.5 Hz,1H), 5.41 (s, 2H), 4.66 (s, 2H), 3.77 (s, 3H), 2.52 (s, 3H). 13 C NMR (125 MHz, d -DMSO) δ 168.49, 160.12, 157.65, 154.36, 152.78, 150.28, 147.43, 133.76,125.51, 124.38, 122.28, 121.45, 107.71, 102.26, 102.18, 101.33, 55.87, 49.42,46.46, 26.17; HRMS(ESI): Calcd for C 22 H 21 N6O2 + [ M +H] + : 401.172 1, found: 401.1728.
[0059] Example 12: 4-[2-methyl-7-(3-pyridylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I12) Synthetic Method 1. 2-Methyl-4-chloro-7-(3-pyridylmethyl)pyrrolo[2,3- d Pyrimidine (103 mg, 0.4 mmol), 2 (108 mg, 0.5 mmol). 65 mg of the target compound was obtained as a reddish-brown solid, yield: 40.6%, melting point: 163-164 °C; 1 H NMR (500 MHz, d -DMSO) δ 10.66 (s, 1H), 8.53 (d, J = 1.5 Hz, 1H), 8.47(dd, J = 4.6, 1.1 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.33 (dd, J= 7.8, 4.8 Hz, 1H), 7.23 (d, J = 3.6 Hz, 1H), 7.18 (d, J = 8.7 Hz, 1H), 6.65 (d, J = 2.7 Hz, 1H), 6.62 (dd, J = 8.7, 2.7 Hz, 1H), 5.53 (d, J = 3.6 Hz, 1H), 5.40 (s, 2H), 4.65 (s, 2H), 3.77 (s, 3H), 2.55 (s, 3H). 13 C NMR (125 MHz, d -DMSO)δ 168.46, 160.03,157.58, 154.29, 152.60, 149.22, 149.20, 135.65, 134.02, 133.71, 125.17,124.32, 124.15, 121.44, 107.67, 102.21, 101.22, 55.85, 49.40, 45.17, 26.22;HRMS(ESI): Calcd for C 22 H 21 N6O2 + [ M +H] + : 401.172 1, found: 401.172 9.
[0060] Example 13: 4-{2-methyl-7-[(6-methylpyridin-3-yl)methyl]pyrrolo[2,3- d Pyrimidin-4-yl-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I13) Synthetic Method 1. 2-Methyl-4-chloro-7-((6-methylpyridin-3-yl)methyl)pyrrolo[2,3- d ]Pyrimidine (109 mg, 0.4 mmol), 2 (107 mg, 0.5 mmol), yielded 67 mg of the target compound as a white solid, yield: 40.4%, melting point: 135-136 °C; 1 H NMR (500 MHz, d -DMSO) δ 10.66 (s, 1H), 8.40 (d, J = 2.0 Hz, 1H), 7.49 (dd,J = 8.0, 2.5 Hz, 1H), 7.20 (d, J = 3.5 Hz, 1H), 7.19 – 7.15 (m, 2H), 6.65 (d, J = 3.0 Hz, 1H), 6.61 (dd, J = 8.5, 3.0 Hz, 1H), 5.51 (d, J = 3.5 Hz, 1H), 5.34 (s, 2H), 4.64 (s, 2H), 3.77 (s, 3H), 2.55 (s, 3H), 2.41 (s, 3H). 13 C NMR (125 MHz, d -DMSO) δ 168.46, 159.96, 157.59, 157.56, 154.25, 152.55, 148.61,136.06, 133.69, 130.93, 125.11, 124.28, 123.38, 121.45, 107.66, 102.21,101.12, 99.98, 55.84, 49.40, 44.96, 26.22, 24.13;HRMS(ESI): Calcd forC 23 H 23 N6O2 + [ M +H] + : 415.187 7, found: 415.188 5.
[0061] Example 14: 4-(2-methyl-5-iodo-7-benzylpyrrolo[2,3- d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I14) Synthetic Method 1. 2-Methyl-4-chloro-5-iodo-7-benzylpyrrolo[2,3- d ]Pyrimidine (153 mg, 0.4 mmol), 2 (106 mg, 0.5 mmol), yielded 83 mg of the target compound as a white solid, yield: 39.5%, melting point: 200-202 °C; 1 H NMR (600 MHz, d -DMSO) δ 10.65 (s, 1H, NH), 7.61 (s, 1H), 7.34 (t, J= 7.8Hz, 2H), 7.28 (d, J = 9.0 Hz, 2H), 6.60 (d, J = 3.0 Hz, 1H), 6.46 (d, J = 8.4 Hz, 1H), 6.40 (dd, J = 9.0, 2.6 Hz, 1H), 5.75 (d, J = 1.8 Hz, 1H), 5.38 (s, 2H), 4.26 (s, 2H), 3.68 (s, 3H), 2.59 (s, 3H); 13 C NMR (125 MHz, d -DMSO) δ 168.07, 160.65, 156.16, 153.88, 153.05, 137.96, 133.12, 131.58, 129.14, 128.11, 128.00, 127.04, 118.38 , 108.18 , 107.04 , 102.85 , 55.75 , 52.66 , 51.26 ,47.65 , 26.05.HRMS(ESI): Calcd for C 23 H 21 IN5O2 + [ M +H] + : 526.073 4, found: 526.0744.
[0062] Example 15: 4-(2-methyl-5-acetyl-7-benzylpyrrolo[2,3- d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I15) Synthetic Method 1. 2-Methyl-4-chloro-5-(trimethylsilylethynyl)-7-benzylpyrrolo[2,3- d Pyrimidine (142 mg, 0.4 mmol), 2 (106 mg, 0.5 mmol), yielded 53 mg of the target compound as a yellow solid, yield: 31.4%, melting point: 270 °C (carbonized). 1 H NMR (500 MHz, d -DMSO) δ 10.62 (s, 1H), 8.19 (s, 1H),7.39 – 7.26 (m, 5H), 6.53 (d,J = 2.6 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 6.32(dd, J = 8.8, 2.6 Hz, 1H), 5.43 (s, 2H), 4.44 (s, 2H), 3.67 (s, 3H), 2.57 (s,3H), 2.01 (s, 3H); 13 C NMR (125 MHz, d -DMSO) δ 191.22, 167.68, 161.28, 156.11,154.67, 154.18, 137.71, 133.25, 132.27, 129.18, 128.15, 127.94, 124.23,118.44, 118.19, 107.13, 102.58, 100.46, 55.80, 50.54, 47.95, 27.83,26.09.HRMS(ESI): Calcd for C 25 H 24 N5O3 + [ M +H] + : 442.187 4, found: 442.188 0.
[0063] Example 16: 4-[2-methyl-5-(furan-3-yl)-7-benzylpyrrolo[2,3-] d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I16) I14 (243 mg, 0.46 mmol), pinacol furan-3-boronate (175 mg, 0.9 mmol), X-Phos (37 mg, 0.11 mmol), palladium acetate (8.2 mg, 0.04 mmol), and Cs₂CO₃ (268 mg, 0.8 mmol) were dissolved in 1,4-dioxane / water (4.8 mL). v : vIn a mixture of 5:1 (AcOEt : PE = 0 ~ 40%), the reaction was microwave-heated to 120℃ for 35 min. The reaction was monitored by TLC until complete. The reactants were poured into 80 mL of ice water, extracted with AcOEt (30 mL × 3), washed with saturated NaCl water, and dried over anhydrous Na₂SO₄. After evaporation of the solvent under reduced pressure, the crude product was separated by Flash column chromatography (AcOEt : PE = 0 ~ 40%) to give 178 mg of the target compound as a light yellow solid, yield: 77%. Melting point: 185-187℃; 1 H NMR (500 MHz, d -DMSO) δ 10.55 (s, 1H), 7.45 (s,1H), 7.37 – 7.29 (m, 5H), 7.29 (d, J = 7.0 Hz, 2H), 6.45 (d, J = 9.0 Hz, 1H), 6.39 (d, J = 2.5 Hz, 1H), 6.32 (s, 1H), 6.17 (dd, J = 9.0, 2.8 Hz, 1H), 5.43 (s,2H), 4.24 (s, 2H), 3.60 (s, 3H), 2.58 (s, 3H); 13 C NMR (125 MHz, d -DMSO) δ 167.99, 160.12, 155.85, 154.66, 153.40, 142.94, 138.99, 138.22, 131.38, 129.13, 128.02, 127.96, 125.37 , 125.03 , 119.09 , 118.52 , 110.90 ,107.80 , 106.98 , 103.48 , 102.12 , 55.73 , 51.41 , 47.55 , 26.10.HRMS(ESI):Calcd for C 27 H 24 N5O3 + [ M +H] + : 466.187 4, found: 466.188 1.
[0064] Example 17: 4-(2-chloro-7-benzylpyrrolo[2,3-) d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I17) Synthetic Method 4. V1 (60 mg, 0.13 mmol), cesium carbonate (86 mg, 0.26 mmol), DMF (4 mL). 50 mg of the target compound was obtained as a white solid, yield: 91.8%. Melting point: 198–200 °C. 1 H NMR (600 MHz, d -DMSO) δ10.76 (s, 1H), 7.35 – 7.25 (m, 5H), 7.20 (d, J = 7.2 Hz, 2H), 6.67 – 6.62 (m,2H), 5.62 (d, J = 3.6 Hz, 1H), 5.35 (s, 2H), 4.63 (s, 2H), 3.78 (s, 3H).HRMS(ESI): Calcd for C 22 H 19 ClN5O2 + [ M +H] + : 420.122 2, found: 420.123 1.
[0065] Example 18: 4-(7-benzylpyrrolo[2,3- d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I18) I17 (57 mg, 0.14 mmol) was dissolved in 6 mL of ethyl acetate, and diisopropylethylamine (48 μL, 0.28 mmol) and palladium on carbon (30 mg, 10%, 45% wt) were added. The reaction was carried out under a hydrogen atmosphere for 10 h, and the reaction was monitored by TLC until complete. The palladium on carbon was removed by filtration through diatomaceous earth, and the crude product was subjected to Flash column chromatography (AcOEt: PE = 0 ~ 50%) to give 41 mg of the target compound as a pale red solid, yield: 76.0%. Melting point: 241-242℃; 1 H NMR (500 MHz, d -DMSO) δ 10.67 (s, 1H), 8.43 (s,1H), 7.33 – 7.28 (m, 3H), 7.27 – 7.18 (m, 4H), 6.65 (d, J = 2.5 Hz, 1H), 6.62(dd, J = 8.5, 3.0 Hz, 1H), 5.60 (d,J = 3.5 Hz, 1H), 5.39 (s, 2H), 4.66 (s, 2H), 3.77 (s, 3H).HRMS(ESI): Calcd for C 22 H 20 N5O2 + [ M +H] + : 386.161 2, found: 386.1619.
[0066] Example 19: 4-(2,5-dichloro-7-benzylpyrrolo[2,3- d Pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I19) Synthetic Method 4. V2 (99 mg, 0.2 mmol), cesium carbonate (130 mg, 0.4 mmol), DMF (5 mL). 79 mg of the target compound was obtained as a white solid, yield: 86.9%. Melting point: 175–177 °C. 1 H NMR (500 MHz, d -DMSO) δ10.70 (s, 1H, NH), 7.64 (s, 1H), 7.39 – 7.29 (m, 2H,), 7.34 – 7.21 (m, 2H), 6.95 (d, J = 8.5 Hz, 1H), 6.60 (d, J = 3.0 Hz, 1H), 6.47 (dd, J = 8.5, 2.8 Hz, 1H),5.76 (s, 1H), 5.35 (s, 2H), 4.39 (s, 2H), 3.71 (s, 3H).HRMS(ESI): Calcd forC 22 H 18 Cl2N5O2 + [ M +H] + : 454.083 2, found: 454.083 8.
[0067] Example 20: 4-[2,5-dichloro-7-(4-fluorobenzyl)pyrrolo[2,3- d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (Compound I20) Synthetic Method 4. V3 (75 mg, 0.15 mmol), cesium carbonate (96 mg, 0.3 mmol), DMF (4 mL). 62 mg of the target compound was obtained as a yellow solid, yield: 87.8%. Melting point: 185-187 °C; 1 H NMR (500 MHz, d -DMSO) δ10.70 (s, 1H), 7.64 (s, 1H), 7.34 (dd, J = 8.7, 5.5 Hz, 2H), 7.18 (t, J = 8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 1H), 6.59 (d, J = 2.8 Hz, 1H), 6.46 (dd, J = 8.9, 2.8 Hz,1H), 5.33 (s, 2H), 4.38 (s, 2H), 3.71 (s, 3H).HRMS(ESI): Calcd forC 22 H 17 Cl2FN5O2 + [ M +H] + : 472.073 8, found: 472.074 6.
[0068] Example 21: 4-[2-chloro-6-methyl-7-(4-fluorophenylmethyl)pyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I21) Synthetic Method 4. V4 (98 mg, 0.2 mmol), cesium carbonate (130 mg, 0.4 mmol), DMF (3 mL). The crude product was separated by Flash column chromatography (AcOEt:PE = 2:3) to give 73 mg of the target compound as a white solid, yield: 80.8%. Melting point: 232-234℃; 1 H NMR (500 MHz, d-DMSO) δ 10.72 (s, 1H), 7.26 – 7.22 (m,1H), 7.17 – 7.08 (m, 4H), 6.67 – 6.62 (m, 2H), 5.45 (s, 1H), 5.35 (s, 2H), 4.60 (s, 2H), 3.77 (s, 3H), 2.16 (s, 3H).HRMS(ESI): Calcd for C 23 H 20 ClFN5O2 + [ M +H] + : 452.128 4, found: 452.129 1.
[0069] Example 22: 4-[2-(furan-3-yl)-7-benzylpyrrolo[2,3-] d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I22) I17 (63 mg, 0.15 mmol), pinacol furan-3-boronate (35 mg, 0.18 mmol), X-Phos (14.3 mg, 0.03 mmol), palladium acetate (3.4 mg, 0.015 mmol), and Cs₂CO₃ (68 mg, 0.21 mmol) were dissolved in 1,4-dioxane / water (3.6 mL). v : v In a mixture of AcOEt and PE (5:1), the reaction was microwaved to 120°C for 30 min. The reaction was monitored by TLC until complete. The reactants were poured into 60 mL of ice water, extracted with AcOEt (30 mL × 3), washed with saturated NaCl water, and dried over anhydrous Na₂SO₄. After evaporation of the solvent under reduced pressure, the crude product was separated by Flash column chromatography (AcOEt : PE = 0 ~ 45%) to give 47 mg of a white solid, yield: 69.4%. Melting point: 194-196°C. 1 H NMR (500 MHz, d -DMSO) δ 10.67 (s, 1H), 8.39 – 8.38 (m,1H), 7.77 (t, J = 1.7 Hz, 1H), 7.33 – 7.31 (m, 4H), 7.27 (d, J = 3.5 Hz, 1H),7.27 – 7.22 (m, 2H), 7.09 – 7.08 (m, 1H), 6.66 (d,J = 3.0 Hz, 1H), 6.64 (dd, J =8.5, 3.0 Hz, 1H), 5.56 (d, J = 3.5 Hz, 1H), 5.41 (s, 2H), 4.73 (s, 2H), 3.78(s, 3H).HRMS(ESI): Calcd for C 26 H 22 N5O3 + [ M +H] + : 452.171 7, found: 452.171 9.
[0070] Example 23: 4-[2-(4-cyanoanilino)-7-benzylpyrrolo[2,3- d [Pyrimidin-4-yl]-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one (compound I23) I17 (63 mg, 0.15 mmol), 4-cyanoaniline (19 mg, 0.16 mmol), Xant-Phos (3.5 mg, 0.006 mmol), Pd2(dba)3 (3.4 mg, 0.015 mmol), and Cs2CO3 (74 mg, 0.225 mmol) were dissolved in 1,4-dioxane (3 mL) and refluxed under nitrogen protection for 5 h. The reaction was monitored by TLC until complete. Insoluble matter was removed by filtration, followed by washing with ethyl acetate, evaporation of the solvent under reduced pressure, dissolution in dichloromethane, and standing. A solid precipitated was obtained, filtered, and dried to give 27 mg of the target compound as a white solid, yield: 35.9%. Melting point: 229-231 °C. 1 H NMR (500 MHz, d -DMSO) δ 9.74 (s, 1H), 7.97(d, J = 9.0 Hz, 2H), 7.65 (d, J = 9.0 Hz, 2H), 7.36 – 7.32 (m, 2H), 7.27 – 7.24(m, 4H), 7.10 (d, J = 3.5 Hz, 1H), 6.66 – 6.63 (m, 2H), 5.54 (d, J = 3.5 Hz, 1H),5.33 (s, 2H), 4.68 (s, 2H), 3.78 (s, 3H);HRMS(ESI): Calcd for C29 H 24 N7O2 + [ M +H] + :502.198 6, found :502.199 2.
[0071] Example 24: In vitro tumor cell proliferation inhibition assay of compound I 1. Test method: Human non-small cell lung cancer A549 cells, human cervical cancer HeLa cells, and human glioma U251 cells were given different concentrations of compound I (prepared in Examples 1-23) and incubated in a 37°C, 5% CO2 incubator for 48 h. The inhibition rate of the compound on tumor cells was determined by the CCK-8 assay. The positive control drugs were colchicine and paclitaxel. The results are shown in Table 1.
[0072] 2. Experimental Results: Table 1. Inhibitory activity of the compounds of the present invention against the proliferation of A549, HeLa, and U251 tumor cells. Example 25: In vitro microtubule aggregation inhibition experiment of representative compounds 1. Test drugs: Compounds I1, I2, I10, I11, I14, I17, I19 obtained according to the above examples, colchicine, and dimethyl sulfoxide (DMSO, control).
[0073] 2. Test methods: Tubulin and a series of analyte compounds at varying concentrations were added to a PEM buffer (containing 100 mM MPIPES, 1 mM MgCl2, and 1 mM EGTA) and thoroughly mixed. 1 mM GTP and 5% glycerol were also added to the buffer. Using a Molecular Devices SPECTRA MAX190 spectrophotometer, absorbance (OD) at 340 nm was measured every 1 minute for a total of 20 minutes. The IC50 was calculated using the plateau absorbance values. 50 The drug concentration that inhibited 50% of tubulin aggregation after 20 minutes is indicated. GraphPad Prism analysis was used, and results are expressed as mean ± standard deviation (x ± s), as shown in Table 2.
[0074] Table 2. Inhibitory activity of representative compounds of the present invention against tubulin aggregation Example 26: VEGFR2 Inhibition Experiment of Representative Compounds 1. Test drugs: Compounds I1, I2, I10, I11, I14, I17, I19 obtained according to the above examples, colchicine, and dimethyl sulfoxide (DMSO, control).
[0075] 2. Test methods: All enzymatic reactions were carried out at 30°C for 40 minutes. Each 50 µL reaction mixture contained 40 mM Tris (pH 7.4), 10 mM MgCl2, 0.1 mg / ml bovine serum albumin (BSA), 1 mM dithiothreitol (DTT), 10 µM adenosine triphosphate (ATP), 0.2 μg / ml phosphoinositol-3 kinase (PI3 kinase), and 100 µM lipid substrate. The compounds were diluted with 10% dimethyl sulfoxide (DMSO), and 5 µL of the diluent was added to each 50 µL reaction mixture to bring the final DMSO concentration to 1%. The Kinase-Glo Plus luminescent kinase assay kit was used for detection. This kit measures kinase activity by quantifying the amount of ATP remaining in the solution after the kinase reaction. The detected luminescent signal was positively correlated with ATP content and negatively correlated with kinase activity. Nonlinear regression analysis was performed using Prism GraphPad software, and the IC50 was calculated using standardized dose-response fitting. 50 The values are shown in Table 3.
[0076] Table 3. VEGFR2 inhibitory activity of representative compounds of the present invention Example 27: In vivo safety evaluation of compounds I1, I2, and I11 in mice 1. Test drug: Compounds I1, I2, and I11 obtained according to the above examples, paclitaxel.
[0077] 2. Test methods: Compounds I1, I2, I11, and paclitaxel were dissolved in physiological saline solution containing 2% dimethyl sulfoxide (DMSO), 40% PEG-300, and 5% Tween-80 to prepare corresponding drug solutions. Kunming mice were administered the drugs via intraperitoneal injection, with three mice in each group. The experimental groups were set as follows: solvent control group (administered an equal volume of the above solvent); I1 was administered in three dose groups: 30 mg / kg, 20 mg / kg, and 10 mg / kg; I2 was administered in two dose groups: 20 mg / kg and 10 mg / kg; I11 was administered as a single dose of 20 mg / kg; and paclitaxel was administered in two dose groups: 20 mg / kg and 10 mg / kg. The administration frequency was once every 2 days, for a total of 14 days.
[0078] Experimental results showed that at a dose of 30 mg / kg, I1 exhibited significant systemic toxicity. The experiment was prematurely terminated after 1-2 doses, and the mice were euthanized due to severe drug toxicity and a near-death state. For animal ethics and experimental safety reasons, subsequent animal experiments at 30 mg / kg doses of I2 and I1 were not conducted. Mice in the 20 mg / kg paclitaxel group experienced rapid weight loss and died after severe diarrhea. In contrast, I1, I2, and I11 had a wider safety window, were well tolerated by mice, and no systemic toxicity or adverse reactions were observed in any of the treatment groups during the 14-day toxicity observation period; no animal deaths were reported. (See attached results). Figure 1 It should be noted that the endpoint of the curve represents the time point at which the test drug caused severe toxicity, and the experiment was terminated.
[0079] Example 28: Evaluation of the efficacy of compound I2 in nude mouse xenografts of HeLa cells for cervical cancer. 1. Test drug: Compound I2, paclitaxel, obtained according to the above examples.
[0080] 2. Test methods: HeLa cells in the logarithmic growth phase were collected, with a cell count of 2 × 10⁻⁶. 6 Each HeLa tumor sample was suspended in 50 μL of basal culture medium and thoroughly mixed with 50 μL of Matrigel. The mixture was then subcutaneously injected into the right dorsal flank of each mouse. Drug administration began after the average HeLa tumor volume reached 100 mm³ (tumor size was measured using calipers; tumor volume was calculated using the formula: V = a × b). 2 ×0.5); where a is the longest diameter of the tumor and b is the shortest diameter of the tumor). Mice were randomly assigned to four experimental groups, with six mice in each group. The drug administration groups were as follows: solvent control group (administered a solvent of equal volume prepared from 2% dimethyl sulfoxide, 40% PEG-400, 5% Tween-80 and 53% physiological saline); positive control group (paclitaxel administration, dose 10 mg / kg); and two I2 dosage groups (10 mg / kg and 20 mg / kg). The solvent used for I2 and paclitaxel was consistent with the solvent used in the HeLa xenograft tumor model, and the in vivo dosage was determined with reference to the results of the previous maximum tolerated dose (MTD) study. Each group was administered the drug via intraperitoneal injection three times a week for two consecutive weeks. During the administration period, the tumor volume and mouse weight were recorded every two days. When the tumor volume in the solvent group reached approximately 1200 mm³, the in vivo experiment was terminated, and the tumor was removed and weighed after the experiment.
[0081] The results showed that I2 significantly inhibited the growth of HeLa xenografts, with both tumor volume and weight significantly reduced. The tumor growth inhibition rate (TGI) of I2 at doses of 10 mg / kg and 20 mg / kg reached 73.69% and 74.23%, respectively, demonstrating superior antitumor activity compared to 10 mg / kg paclitaxel (see [link to study]). Figure 2 Throughout the dosing period, the mice in the test compound administration group did not experience a significant decrease in body weight, and no obvious toxicity-related adverse reactions were observed; suggesting that I2 has good in vivo tolerability at the above effective dosage.
[0082] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., refer to specific features, structures, materials, or characteristics described in connection with that embodiment or example, which are included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.
[0083] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1,4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3-) d Pyrimidine-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds, characterized in that, Its structural formula is shown in Formula I: Among them, R 1 The following are compounds: H, alkyl groups with 1 to 6 carbon atoms, cycloalkyl groups with 3 to 6 carbon atoms, alkylamino groups with 1 to 6 carbon atoms, dialkylamino groups with 1 to 6 carbon atoms, cycloalkylamino groups with 3 to 6 carbon atoms, alkoxy groups with 1 to 6 carbon atoms, cycloalkoxy groups with 3 to 6 carbon atoms, halogens, vinyl groups, ethynyl groups, (hetero)aryl groups of 5 to 6 membered rings, (hetero)arylamino groups of 5 to 6 membered rings, and (hetero)aryloxy groups of 5 to 6 membered rings; R 2 H, alkyl groups with 1 to 6 carbon atoms, cycloalkyl groups with 3 to 6 carbon atoms, halogens, vinyl groups, ethynyl groups, acetyl groups, and (hetero)aryl groups with 5 to 6 membered rings; R 3 It is H, an alkyl group with 1 to 6 carbon atoms, or a cycloalkyl group with 3 to 6 carbon atoms; R 4 It can be H, alkyl groups with 1 to 3 carbon atoms, or halogens; X is CR 5 Or N; where R 5 It can be H, alkyl groups with 1 to 3 carbon atoms, or halogens; Y is CR 6 Or N; where R 6 The group can be H, alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 6 carbon atoms, alkoxy with 1 to 6 carbon atoms, cycloalkoxy with 3 to 6 carbon atoms, alkylamine with 1 to 6 carbon atoms, cycloalkylamine with 3 to 6 carbon atoms, halogen, cyano, methanesulfonyl, ester, carboxyl, amide, nitro, or amino.
2. The 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3-]] according to claim 1 d Pyrimidine-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds, characterized in that, Its structural formula is any one of the following: 。 3. A 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3- d The method for preparing pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxaline-2-one compounds, as described in any one of claims 1 to 2, is applied to the method for preparing 4-(2,5,6-polysubstituted-7-arylmethylpyrrolo[2,3-)-one compounds. d The compound, pyrimidin-4-yl)-7-methoxy-1,2,3,4-tetrahydroquinoxalin-2-one, is characterized in that its preparation is carried out via the following reaction route:
4. The preparation method according to claim 3, characterized in that, The preparation method includes the following steps: reacting compound II and compound 1 in a solvent in the presence of acid or under neutral conditions to obtain compounds I1~I5, I7, I9~I15 of general formula I; hydrolyzing I5 under alkaline conditions to obtain I6; reducing I7 under palladium-carbon catalytic hydrogenation to obtain I8; and coupling I14 with SUZUKI under palladium reagent and phosphine ligand catalysis to obtain I16. Alternatively, compound III can be reacted with compound 2 in a solvent in the presence of a base to give compound IV, which is then acylated with chloroacetyl chloride to give compound V. These compounds are then cyclized under basic conditions to give compounds I17, I19–I21 of general formula I. I17 is dechlorinated under palladium-carbon catalytic hydrogenation to give I18. I17 is then coupled with a SUZUKI reaction catalyzed by a palladium reagent and a phosphine ligand to give I22, and coupled with a Buchwald-Hartwig reaction to give I23.
5. A pharmaceutical composition, characterized in that, The active pharmaceutical ingredient includes the compound of any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof.
6. A combination drug composition, characterized in that, It comprises the compound of claim 1 and at least one other therapeutic agent selected from the following: taxane microtubule stabilizers, vincristine alkaloids, histone deacetylase inhibitors, and immune checkpoint inhibitors.
7. Use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating tumors.
8. The application according to claim 7, characterized in that: The tumor is any one of the following: blood cancer, ovarian cancer, prostate cancer, testicular cancer, melanoma, pancreatic cancer, lymphoma, breast cancer, cervical cancer, stomach cancer, brain cancer, kidney cancer, lung cancer, liver cancer, or colon cancer.
